Heart risks of glucose controlled drugs unnoticed in clinical trials

According to research published in journal The Lancet Diabetes & Endocrinology shows that the glucose-lowering drugs might increase the risk of heart failures. In actual this risk is overlooked and ignored in the clinical trials. The study further shows that antidiabetes drugs can cause cardiovascular diseases among the sufferers. It further prompted that the FDA and EMA had made new regulations from cardiovascular outcomes for new antidiabetes drugs. According to the researchers this should not be overlooked. Overlooking may create more problems threatening problems. The trials should be managed in logical manner so that no aspect is left out. According to Professor John McMurray of The University of Glasgow explains, “Fortunately, some trials in progress are taking heart failure into account as a secondary outcome. But many others are neglecting to report this important complication as a key trial outcome. Until heart failure is systematically evaluated in clinical trials, the cardiovascular safety of antidiabetes drugs will remain uncertain.”